Kraig Biocraft Laboratories Inc (KBLB)

[TRUISM]

JENS KLEIN AS MANAGING DIRECTOR OF AMSILK GMBH


APPOINTMENT OF JENS KLEIN AS MANAGING DIRECTOR OF AMSILK GMBH

Click For Amsilk Press Release



Planegg, Germany, May 23, 2014 / B3C newswire / - Mr. Jens Klein was appointed managing director of AMSilk GmbH, Planegg, as of March 15, 2014. He succeeds Mr. Axel Leimer, AMSilk’s former CEO, who had successfully run the company for six years until February 28, 2014.

As CEO Mr. Klein is responsible for the strategic positioning and the future growth of the company.

Most recently Mr. Klein worked for Evonik Industries AG. In 2011 Evonik acquired nanoresins AG and Hanse Chemie AG. Mr. Klein was a member of the executive committee of both companies since 2006. In these functions he had a significant impact on the growth of both companies, the integration of new technologies, the optimization of manufacturing processes as well as the international expansion.

Previously, he was a member of the executive board of Mulligan BioCapital AG, Hamburg and Munich. Mulligan used to be a long-term investor in medical technology, biotechnology and high technology enterprises in the US and Europe. Among other responsibilities Mr. Klein shared responsibilty for the initial public offerings of two portfolio companies as well as several trade sales to strategic investors. Prior to joining Mulligan he was the commercial head and managing director of subsidiaries of Fresenius AG, Bad Homburg.

With regard to his new tasks at AMSilk GmbH Mr. Klein stated, „AMSilk has the unique potential to market spider silk protein across various application areas. The key goal is to position the product successfully in high revenue markets and to generate additional collaborations and licensing deals.“.

Mr. Helmut Jeggle, managing director of AT Newtec GmbH and representative of AMSilk’s largest shareholder commented, „Our thanks go to Mr. Leimer for his magnificent performance ever since the founding of AMSilk in 2008 and for his outstanding personal commitment that allowed him to take AMSilk to where it is today. We also wish Mr. Klein our best for the challenges ahead.“

Dr. Matthias Kromayer, chairman of the board of AMSilk GmbH and member of the executive committee of MIG Verwaltungs AG mentioned, „We feel enthusiastic that we managed to hire Jens Klein who happens to be not only an expert with comprehensive industry knowledge but also a man who can skillfully formulate ambitious goals and then turn them into reality. Beyond this he combines extensive experience in strategically positioning companies, building sales organizations, managing corporate finances and working with the financial markets with his broad skills and know-how in high technology markets."

==============

Leimer "Quotables" From C&EN Article-Spider Silk Poised For Commercial Entry-March 3,2014


Click For C&EN Article

“This is scalable technology,” Managing Director Axel H. Leimer says. “If someone ordered 1 ton, we could make it. We have already made a half a ton,” he says. For the first time, a company is producing recombinant spider silk that is as tough and strong as the silk from a spider, Leimer claims.

Leimer is hoping that AMSilk’s know-how will enable it to roll out products generating annual sales in the next couple of years of more than $10 million. He is targeting sales of more than $100 million once large-scale production of synthetic fibers is under way.

Leimer hopes that, by the end of 2015, AMSilk’s spider silk protein will also be on the market as a dip coating for silicone breast implants. The protein changes the properties of the implant, making its hydrophobic surface slightly negatively charged and reducing the body’s reaction to it, Leimer says. “It’s a double-digit million-dollar market for spider silk.”

Large-scale output for products such as fibers and high-performance textiles will come after 2015, Leimer says. Longer term, AMSilk is eyeing capsules for drug delivery and miniature spider silk beads for vaccines that would get around the need for refrigeration.
Leimer is convinced that, even from the outset, the market will be able to support several players.

TRUTH